Goldman Sachs analyst Patrick Donnelly downgraded Quest Diagnostics (DGX) to Neutral and lowered his price target for the shares to $90 from $110. The analyst also downgraded his coverage view of Labs from Attractive to Neutral and removed LabCorp (LH) from his firm's Americans Conviction List. Donnelly's "incrementally more cautious stance" reflects his expectation for continued downward pressure to consensus estimates from ongoing pricing pressure, a "muted" volume outlook, and uncertainty regarding ongoing commercial payer dynamics. He sees an "uneven path to long-term organic volume growth" for Quest.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

Quest Diagnostics announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease, supported by research as useful for an early diagnosis of AD. The test is the latest addition to the AD-Detect portfolio of blood tests for assessing the risk of Alzheimer's Disease, which also includes testing for an array of AD biomarkers, including p-tau181 and amyloid beta proteins, as well as Apolipoprotein E isoform and plasma testing, for patients with cognitive impairment. The test is expected to be available for ordering on April 26.